Stocksigma LogoStocksigma Logo

Glenmark Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

■ Revenue: 42,473 (-29.8% YoY | +5.7% QoQ) ■ EBITDA: 8,638 (-63.4% YoY | +7.3% QoQ) ■ EBITDA Margin (%): 20.3 (-1868 bps YoY | +31 bps QoQ) ■ PAT: 2,638

Glenmark Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

Glenmark Pharmaceuticals Ltd · Outcome · 05 Nov 2026, 10:34 pm

Glenmark Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 42,473 (-29.8% YoY | +5.7% QoQ) ■ EBITDA: 8,638 (-63.4% YoY | +7.3% QoQ) ■ EBITDA Margin (%): 20.3 (-1868 bps YoY | +31 bps QoQ) ■ PAT: 2,638 (-56.8% YoY | -45.4% QoQ) ■ EPS (INR): 9.34 (-56.8% YoY | -45.4% QoQ)

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements